<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sabbagh, Marwan</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Negative Florbetaben PET Scan Excludes the Presence of Amyloid Pathology</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-10</style></pages><abstract><style  face="normal" font="default" size="100%">There is a strong correlation between florbetaben (an F-labeled β-amyloid-targeted tracer) uptake and amyloid pathology. This article presents results of the Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-Amyloid Compared to Histopathology trial (ClinicalTrials.gov identifier NCT01020838). These results support the use of florbetaben as a valuable diagnostic tool for the exclusion of Alzheimer's disease or differential diagnosis of dementia as the cause of cognitive decline.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>